Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Sep 06 04:00PM ET
78.72
Dollar change
-0.05
Percentage change
-0.06
%
IndexNDX, S&P 500 P/E96.21 EPS (ttm)0.82 Insider Own0.21% Shs Outstand1.25B Perf Week-0.92%
Market Cap98.01B Forward P/E10.94 EPS next Y7.20 Insider Trans-0.72% Shs Float1.24B Perf Month6.38%
Income1.05B PEG16.09 EPS next Q1.56 Inst Own84.87% Short Float1.35% Perf Quarter23.29%
Sales27.78B P/S3.53 EPS this Y-43.67% Inst Trans0.85% Short Ratio2.41 Perf Half Y6.87%
Book/sh14.67 P/B5.37 EPS next Y90.10% ROA1.82% Short Interest16.77M Perf Year6.03%
Cash/sh3.37 P/C23.35 EPS next 5Y5.98% ROE5.34% 52W Range62.07 - 87.86 Perf YTD-2.83%
Dividend Est.3.08 (3.91%) P/FCF14.21 EPS past 5Y1.55% ROI2.64% 52W High-10.41% Beta0.20
Dividend TTM3.04 (3.86%) Quick Ratio0.95 Sales past 5Y4.16% Gross Margin77.60% 52W Low26.82% ATR (14)1.47
Dividend Ex-DateSep 13, 2024 Current Ratio1.14 EPS Y/Y TTM-80.78% Oper. Margin36.44% RSI (14)64.13 Volatility1.65% 1.80%
Employees18000 Debt/Eq1.28 Sales Y/Y TTM2.05% Profit Margin3.79% Recom2.17 Target Price84.36
Option/ShortYes / Yes LT Debt/Eq1.18 EPS Q/Q55.31% Payout66.62% Rel Volume1.21 Prev Close78.77
Sales Surprise3.75% EPS Surprise25.05% Sales Q/Q5.46% EarningsAug 08 AMC Avg Volume6.95M Price78.72
SMA203.31% SMA506.79% SMA2007.48% Trades Volume8,430,557 Change-0.06%
Date Action Analyst Rating Change Price Target Change
Jul-08-24Upgrade Raymond James Mkt Perform → Outperform $93
May-01-24Reiterated Maxim Group Buy $90 → $85
Apr-24-24Upgrade HSBC Securities Reduce → Hold $69
Feb-22-24Downgrade Truist Buy → Hold $91 → $82
Nov-09-23Initiated Deutsche Bank Hold $75
Sep-08-23Upgrade BofA Securities Neutral → Buy $88 → $95
Sep-06-23Initiated HSBC Securities Reduce $71
Jul-24-23Reiterated Barclays Equal Weight $81 → $80
May-16-23Upgrade BMO Capital Markets Market Perform → Outperform $90 → $100
Apr-28-23Resumed Piper Sandler Overweight $105
Sep-06-24 09:15AM
Sep-05-24 08:00AM
Sep-04-24 09:25AM
06:52AM
Aug-30-24 05:34PM
02:05PM Loading…
02:05PM
01:46AM
Aug-28-24 06:19PM
Aug-27-24 09:15AM
Aug-26-24 01:19PM
Aug-22-24 09:00AM
Aug-21-24 04:05PM
Aug-20-24 02:00PM
09:00AM
08:30AM
05:12AM Loading…
Aug-19-24 05:12AM
Aug-17-24 01:44AM
Aug-15-24 01:13PM
09:09AM
06:53AM
Aug-14-24 05:01PM
01:59PM
Aug-13-24 08:45AM
Aug-10-24 06:50AM
Aug-09-24 04:34PM
04:11PM
02:43PM
12:22PM
11:15AM
09:45AM
08:23AM Loading…
08:23AM
06:52AM
01:12AM
Aug-08-24 09:45PM
06:00PM
05:16PM
05:15PM
04:20PM
04:12PM
04:11PM
04:05PM
04:02PM
10:15AM
Aug-07-24 09:01AM
Aug-05-24 09:16AM
Aug-04-24 08:00AM
Aug-03-24 06:45AM
Aug-02-24 03:33PM
09:25AM
Aug-01-24 05:50PM
10:01AM
Jul-31-24 04:30PM
09:00AM
Jul-30-24 06:52AM
Jul-29-24 06:00PM
Jul-25-24 04:05PM
09:15AM
06:15AM
Jul-24-24 04:30AM
Jul-23-24 01:00PM
06:32AM
03:52AM
Jul-22-24 06:00PM
01:54PM
04:00AM
Jul-18-24 05:45PM
09:00AM
Jul-17-24 08:50AM
07:15AM
05:52AM
Jul-16-24 06:00PM
08:30AM
Jul-15-24 07:34PM
10:51AM
Jul-14-24 06:30AM
Jul-13-24 11:00AM
Jul-11-24 10:30AM
Jul-10-24 06:00PM
Jul-09-24 06:00AM
Jul-08-24 12:03PM
09:08AM
Jul-04-24 02:13PM
10:01AM
Jul-03-24 06:00AM
Jul-02-24 03:17AM
Jul-01-24 08:45AM
06:55AM
06:50AM
Jun-27-24 03:28PM
Jun-25-24 06:00PM
Jun-23-24 01:38PM
Jun-21-24 03:43PM
03:43PM
12:58PM
09:41AM
09:17AM
09:14AM
08:45AM
07:34AM
07:10AM
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mercier JohannaChief Commercial OfficerAug 28 '24Sale78.039,513742,299105,466Aug 29 03:23 PM
JOHANNA MERCIEROfficerAug 28 '24Proposed Sale78.039,513742,299Aug 28 04:18 PM
Mercier JohannaChief Commercial OfficerAug 13 '24Sale73.985,490406,150114,979Aug 14 02:23 PM
JOHANNA MERCIEROfficerAug 13 '24Proposed Sale73.985,490406,150Aug 13 04:27 PM
Parsey MerdadChief Medical OfficerJul 01 '24Sale68.632,000137,26096,380Jul 01 08:06 PM
GILEAD SCIENCES, INC.10% OwnerApr 02 '24Buy0.76485,250368,7907,345,473Apr 03 06:50 PM
Parsey MerdadChief Medical OfficerApr 01 '24Sale72.962,000145,92096,304Apr 02 06:38 PM
Parsey MerdadChief Medical OfficerFeb 29 '24Sale72.748,230598,62492,706Feb 29 06:35 PM
Parsey MerdadChief Medical OfficerFeb 28 '24Sale73.182,000146,360100,936Feb 29 06:35 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
GILEAD SCIENCES, INC.10% OwnerJan 29 '24Buy21.0015,238,095319,999,99530,061,124Jan 31 05:00 PM
Dickinson Andrew DChief Financial OfficerJan 16 '24Sale85.785,000428,900101,534Jan 17 06:01 PM
Mercier JohannaChief Commercial OfficerJan 09 '24Sale85.238,242702,46682,729Jan 10 03:58 PM
Dickinson Andrew DChief Financial OfficerOct 17 '23Sale80.005,000400,017104,003Oct 18 04:31 PM
Parsey MerdadChief Medical OfficerSep 12 '23Sale76.991,501115,56270,130Sep 13 06:50 PM